Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT02412826
Collaborator
(none)
20
1
24
0.8

Study Details

Study Description

Brief Summary

The purpose of this study is to conduct a pilot test of an abdominal acoustic sensor on patients with acute pancreatitis to determine the correlation of acoustic signals with symptoms reported by the patient.

Condition or Disease Intervention/Treatment Phase
  • Device: Abstats sensor

Detailed Description

This study will use the AbStats device, that measure IAAS (intraabdominal acoustic signals) and intestinal rate and will correlate this data with symptoms reported by patients hospitalized for acute pancreatitis.

The AbStats multi-sensor wireless abdominal monitoring system includes low profile acoustic sensors that are applied to the anterior abdominal wall with Tegaderm and monitors sounds emanating from the GI tract. The acoustic sensors continuously and non-invasively monitor and capture audio signals representing GI and abdominal wall function. The captured data is recorded in a synchronized manner from all sensors.

We will place the AbStats sensor on all patients immediately after admission to the hospital. Only study staff trained on the AbStats system will apply the sensors, which fit externally around the abdomen. A physician member of our study staff will be available at all times to help position the device if needed. We will continuously record AbStats acoustic signals for the duration of the hospitalization, with the option to discontinue as clinically required or requested by the provider or patient. A research coordinator will collect clinical data from medical records and enter the data into a secure spreadsheet on CSMC servers. Patients will be asked to keep a daily diary of symptoms. In this diary, the patients will be asked to record information about their food consumption (if any), bowel movements (if any and if associated with contrast from CT imaging or with the use of suppositories/ laxative), specific symptoms, and whether the sensor was removed for any period of time during the day. This will allow us to compare the data collected by the AbStats sensor with self-reported symptoms noted by patients. Physicians and nurses will not be made aware of the AbStats readings so as to eliminate the Hawthorne effect. Patients will be managed according to standard-of-care practice and the data collected by the AbStats device will not be incorporated into clinical care.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis
Study Start Date :
Apr 1, 2015
Anticipated Primary Completion Date :
Apr 1, 2017
Anticipated Study Completion Date :
Apr 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Acute pancreatitis

Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor

Device: Abstats sensor
The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.

Outcome Measures

Primary Outcome Measures

  1. Re-hospitalization for acute pancreatitis [30 days]

    Patients who are re-admitted to the hospital for acute pancreatitis

  2. Ability to PO after discharge [30 days]

    Patients who are able to tolerate oral itnake after discharge

  3. Symptoms [30 days]

    GI symptoms after discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years of age and older

  • diagnosis of acute pancreatitis; must meet at least 2 out of the 3 following critiera:

  1. abdominal pain consistent with acute pancreatitis

  2. serum amylase/lipase >3 times upper limit of normal

  3. characteristic findings from abdominal imaging

  • able to provide informed consent
Exclusion Criteria:
  • unable to provide consent

  • transfer patients

  • cognitive inability to follow directions to maintain sensors in place

  • unable to place abdominal sensors on patients

  • abdominal cellulitis

  • pregnant women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cedars-Sinai Medical Center Los Angeles California United States 90048

Sponsors and Collaborators

  • Cedars-Sinai Medical Center

Investigators

  • Principal Investigator: Elham Afghani, MD, Cedars-Sinai Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Elham Afghani, Assistant Director, Clinical Pancreatology, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT02412826
Other Study ID Numbers:
  • Pro00038455
First Posted:
Apr 9, 2015
Last Update Posted:
Mar 2, 2016
Last Verified:
Mar 1, 2016
Keywords provided by Elham Afghani, Assistant Director, Clinical Pancreatology, Cedars-Sinai Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2016